Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Preservative-Free vs BAK-Preserved Dorzolamide/Timolol in Glaucoma/OH
NCT05857267Phase 4Completed
- Sponsor
- Laboratorios Poen
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dorzolamide + timolol in Open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Laboratorios Poen. Primary endpoint: Ocular Surface Disease Symptoms at 24 weeks. Started Mar 2023; status: completed.
02
Drugs
dorzolamide + timolol
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT05857267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857267.